This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacySafetyDosingSupport & ResourcesSupport & ResourcesVideosMaterials

​​​​The content of this website has been produced in line with the SUTENT® (sunitinib malate) Summary of Product Characteristics for Great Britain. 

Click here for the SUTENT® (sunitinib malate) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.

mRCC Dosing

The recommended starting dose is 50mg capsule taken orally once daily on a 4 weeks on/ 2 weeks off dosing schedule1

Treatment with SUTENT should be continued if the patient is deriving clinical benefit from therapy.

ExampleHow to take SUTENT

SUTENT is for oral administration. It may be taken with or without food. If a dose is missed, the patient should not be given an additional dose. The patient should take the usual prescribed dose on the following day.1 

Sutent dose modification

SUTENT is available in 3 doses to facilitate dose modification in steps of 12.5mg.

Scroll left to view table

Recommended Starting Dose

 50 mg

1st Dose Reduction

37.5 mg

2nd Dose Reduction

25 mg

3rd Dose Reduction

12.5 mg

For GIST and mRCC, dose modifications in 12.5 mg steps may be applied based on individual safety and tolerability. Daily dose should not exceed 75 mg nor be decreased below 25 mg.
For pNET, the recommended dose of Sutent is 37.5 mg taken orally once daily without a scheduled rest period, dose modifications in 12.5mg steps may be applied base on individual safety and tolerability.

For GIST and mRCC only
​​​​​​​Negrier S. Oncology 2012;82:189-196 
Castellano D, et al. Cancer Treat Rev 2013;39:230-240

 SUTENT Summary of Product Characteristics

As with all medications, SUTENT interact with certain drugs. Please refer to the 

SUTENT® Summary of Product Characteristics for Great Britain or the SUTENT® Summary of Product Characteristics for Northern Ireland for a complete list of drug-drug interactions.

AE : Adverse Event 
GIST: Gastrointestinal Stromal Tumour
mRCC: Metastatic Renal Cell Carcinoma
pNET: Pancreatic Neuroendocrine Tumour

ReferencesSUTENT® Summary of Product Characteristics for Great Britain click here. SUTENT® Summary of Product Characteristics for Northern Ireland click here.Negrier S. Oncology 2012;82:189-196.Castellano D, et al. Cancer Treat Rev 2013;39:230-240.
PP-SUT-GBR-0781 August 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​